About Us Strategy & Mission Our Values Our People Our Board Our Collaborations Contact Our Programmes Overview Pipeline C. difficile Infection Enterobacteriaceae ESKAPE Programme Clinical Trials Stewardship Compassionate Use Our Science Discuva Platform Publications Investors Investor Centre Press Releases Financial Reports & Filings Email Alerts Events & Presentations Share Price Data Analyst Coverage Corporate Governance Shareholder Meetings Careers
Preservation of Gut Microbiome Following Ridinilazole versus Fidaxomicin Treatment of Clostridium difficile Infection Preservation of Gut Microbiome Following Ridinilazole versus Fidaxomicin Treatment of Clostridium difficile Infection October 9, 2017 By CKD Digital
Preservation of Gut Microbiome Following Ridinilazole versus Fidaxomicin Treatment of Clostridium difficile Infection
Preservation of Gut Microbiome Following Ridinilazole versus Fidaxomicin Treatment of Clostridium difficile Infection October 9, 2017 By CKD Digital